Tuberculosis (TB) is one of the deadliest infectious diseases worldwide with an estimated 1.6 million deaths per year. Although curable, the number of TB cases is on the rise globally. More and more patients suffer from multidrug-resistant TB, which means that the bacteria has become resistant to the standard drugs used to treat it. Treatment for this type of TB is even more complicated and therefore often fails to cure patients.
New and better treatment options for multidrug-resistant TB are urgently needed. At our new headquarters, we have a state-of-the-art Biosafety Level 3 laboratory (BSL-3), which enables us to study multidrug-resistant TB in an optimal environment.
In collaboration with our long-standing partners, the Ifakara Health Institute in Tanzania and the National Centre for Tuberculosis and Lung Diseases in Georgia, Swiss TPH conducts clinical trials with new TB diagnostics, drugs and vaccines. Our goal is to drive the development of new, life-saving medicines so that all patients can receive appropriate care.
With your help and support, we will work towards improving care and health outcomes for TB patients around the globe.
Please note that donations to Swiss TPH are channeled through the R. Geigy Foundation — a foundation established to support Swiss TPH's activities.
Basellandschaftliche Kantonalbank (BLKB)
R. Geigy-Stiftung Basel
Reference: Research to Tackle Diseases of Poverty
Socinstrasse 57, 4051 Basel
IBAN: CH92 0076 9039 7436 5200 8
More information on www.geigystiftung.ch